AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Fifth circuit denies Impax pay-for-delay petition

15 April 2021 The Fifth Circuit of the Court of Appeals has denied a petition from Impax Laboratories to overturn a decision finding Impax engaged in an illegal pay-for-delay settlement with Endo Pharmaceuticals.

Generics

Teva gets green light for Nexium generic

30 January 2015 The US Food and Drug Administration has approved an application by pharmaceutical company Teva to market a generic version of AstraZeneca’s heartburn drug Nexium.

Americas

Judge denies AstraZeneca’s bid to squash pay-for-delay challenge

27 September 2013 A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

More on this story

Editor's picks

Editor's picks

More features